Take a look back at this week's top news stories.
A new NIH study found women who used chemical hair straightening products to be at a higher risk for uterine cancer than women who didn’t use these products.
The Food and Drug Administration (FDA) has approved Medicine360’s supplemental new drug application to extend the use of its levongestrel-releasing intrauterine system 52mg (LILETTA) to prevent pregnancy for up to 8 years.
Alyssa Dweck, MD, discusses some recent positive data presented at the 2022 NAMS meeting regarding Clairvee (Bonafide Health) as a potential treatment for vaginal odor.
‘Charming Kitten’ believed to be a front for Islamic Revolutionary Guard Corps, according to HHS’ cybersecurity agency.
Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.